期刊文献+

中西医结合降低尿血酸治疗2型糖尿病合并NAFLD的临床研究

A clinical study on treating type 2 diabetes mellitus with NAFLD by the integrative medicine
下载PDF
导出
摘要 目的:探讨西医基础上加粉萆薢治疗2 型糖尿病(Type 2 Diabetes Mellitus,T2DM)患者合并非酒精性脂肪性肝病(Non-Alcoholic Fatty Liver Disease, NAFLD)的可行性。方法:将110 例T2DM 合并NAFLD 患者随机分为两组,其中西药组给予二甲双胍治疗,中西药组在二甲双胍治疗基础上加服粉萆薢,疗程为一个月,记录两组血尿酸水平,比较两组糖脂水平及肝功能,评价临床效果。结果:与西药组相比,中西药组治疗后血尿酸(Serum Uric Acid,SUA)水平得到改善更优(P<0.01)。两组治疗后血清总胆固醇(Total Cholesterol,TC)、甘油三脂(Triglyceride,TG)、低密度脂蛋白胆固醇(Low Density Lipoproteincholesterd,LDL-C)指标和空腹血糖(Glucose,GLU)、空腹胰岛素(Fasting insulin,Fins)指标相比差异显著(P<0.01),此外,中西药组肝功能恢复更有效(P<0.01)。西药组有效患者33 例(60.0%),中西药组有效患者47 例(85.5%),两组治疗有效率相比,差异显著(P<0.01)。结论:二甲双胍作联合粉萆薢可有效降低患者尿血酸水平,改善了患者糖脂水平和肝功能,对T2DM 合并NAFLD 疾病具有良好临床治疗效果。 Objective:To investigate the feasibility of treating T2DM with NAFLD with Fen Bixie (粉萆薢) plus Western medicine. Methods:110 patients with T2DM with NAFLD were randomly divided into two groups.The western medicine group was treated with metformin,and the Chinese and Western medicine group was treated with Fen Bixie more.Results:Compared with the western medicine group,the SUA level in the Chinese and Western medicine group was significantly improved after treatment (P<0.01).There were significant differences in TC,TG,and LDL-C blood lipid parameters and GLU and Fins blood glucose levels after treatment between the two groups (P<0.01).In addition,the liver function improvement in Chinese and Western medicine groups was significantly better (P<0.01). The effective number of patients in the Western medicine group was 33 cases,and the effective rate was 60.0%.The effective number of patients in the Chinese and Western medicine group was 47 cases,and the effective rate was 85.5%(P<0.01).Conclusion:Metformin plus Fen Bixie on type 2 diabetes patients with non-alcoholic fatty liver disease show a good effect,can effectively reduce the level of uric acid, improve glycolipid levels and liver function.
作者 范红顺 Fan Hongshun
出处 《中医临床研究》 2019年第11期56-58,共3页 Clinical Journal Of Chinese Medicine
关键词 二甲双胍 粉萆薢 2型糖尿病 非酒精性脂肪性肝 Metformin Fen Bixie Type 2 diabetes Nonalcoholic fatty liver
  • 相关文献

参考文献2

二级参考文献166

  • 1International Diabetes Federation. IDF Diabetes Atlas. 6thed. Brussels, Belgium: International Diabetes Federation, 2013.Available from: URL: http://www.idf.org/diabetesatlas.
  • 2Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations:from pathophysiology to prevention and management.Lancet 2011; 378: 169-181 [PMID: 21705072 DOI: 10.1016/S0140-6736(11)60614-4].
  • 3Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalenceof diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14[PMID: 19896746 DOI: 10.1016/j.diabres.2009.10.007].
  • 4Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, ButlerPC. Beta-cell deficit and increased beta-cell apoptosis in humanswith type 2 diabetes. Diabetes 2003; 52: 102-110 [PMID: 12502499DOI: 10.2337/diabetes.52.1.102].
  • 5Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell: thelast ten years. Cell 2012; 148: 1160-1171 [PMID: 22424227 DOI:10.1016/j.cell.2012.02.010].
  • 6Quan W, Jo EK, Lee MS. Role of pancreatic β-cell death andinflammation in diabetes. Diabetes Obes Metab 2013; 15 Suppl 3:141-151 [PMID: 24003931 DOI: 10.1111/dom.12153].
  • 7Brownlee M. Biochemistry and molecular cell biology of diabeticcomplications. Nature 2001; 414: 813-820 [PMID: 11742414 DOI:10.1038/414813a].
  • 8Pickup JC, Crook MA. Is type II diabetes mellitus a disease of theinnate immune system- Diabetologia 1998; 41: 1241-1248 [PMID:9794114 DOI: 10.1007/s001250051058].
  • 9Shoelson SE, Lee J, Goldfine AB. Inflammation and insulinresistance. J Clin Invest 2006; 116: 1793-1801 [PMID: 16823477DOI: 10.1172/JCI29069].
  • 10Donath MY, Dalmas é, Sauter NS, B-ni-Schnetzler M. Inflammationin obesity and diabetes: islet dysfunction and therapeutic opportunity.Cell Metab 2013; 17: 860-872 [PMID: 23747245 DOI: 10.1016/j.cmet.2013.05.001].

共引文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部